Nye og genopdagede medikamenter til behandling af tuberkulose

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Nye og genopdagede medikamenter til behandling af tuberkulose. / Kraef, Christian; Lillebæk, Troels; Andersen, Åse Bengård; Kirk, Ole.

In: Ugeskrift for Laeger, Vol. 184, No. 10, V10210783, 2022.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Kraef, C, Lillebæk, T, Andersen, ÅB & Kirk, O 2022, 'Nye og genopdagede medikamenter til behandling af tuberkulose', Ugeskrift for Laeger, vol. 184, no. 10, V10210783. <https://content.ugeskriftet.dk/sites/default/files/scientific_article_files/2022-03/v10210783_web.pdf>

APA

Kraef, C., Lillebæk, T., Andersen, Å. B., & Kirk, O. (2022). Nye og genopdagede medikamenter til behandling af tuberkulose. Ugeskrift for Laeger, 184(10), [V10210783]. https://content.ugeskriftet.dk/sites/default/files/scientific_article_files/2022-03/v10210783_web.pdf

Vancouver

Kraef C, Lillebæk T, Andersen ÅB, Kirk O. Nye og genopdagede medikamenter til behandling af tuberkulose. Ugeskrift for Laeger. 2022;184(10). V10210783.

Author

Kraef, Christian ; Lillebæk, Troels ; Andersen, Åse Bengård ; Kirk, Ole. / Nye og genopdagede medikamenter til behandling af tuberkulose. In: Ugeskrift for Laeger. 2022 ; Vol. 184, No. 10.

Bibtex

@article{5752ba1010c34a0a918b7e1bd28fb61a,
title = "Nye og genopdagede medikamenter til behandling af tuberkulose",
abstract = "Tuberculosis (TB) is still a major challenge for global health, but in recent years there have been several important developments in treatment options. Shorter treatment regimens for latent TB, based on conventional drugs, offer better adherence and fewer side effects, while new and repurposed antibiotics have opened the door to more effective, shorter and less side effect-heavy treatments for drug susceptible TB and multidrug-resistant/extensively drug resistant TB as well as atypical mycobacterioses. This review investigates how these shorter and predominantly oral treatments, in the future, are expected to be used in combination with individualized precision medicine.",
author = "Christian Kraef and Troels Lilleb{\ae}k and Andersen, {{\AA}se Beng{\aa}rd} and Ole Kirk",
year = "2022",
language = "Dansk",
volume = "184",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "10",

}

RIS

TY - JOUR

T1 - Nye og genopdagede medikamenter til behandling af tuberkulose

AU - Kraef, Christian

AU - Lillebæk, Troels

AU - Andersen, Åse Bengård

AU - Kirk, Ole

PY - 2022

Y1 - 2022

N2 - Tuberculosis (TB) is still a major challenge for global health, but in recent years there have been several important developments in treatment options. Shorter treatment regimens for latent TB, based on conventional drugs, offer better adherence and fewer side effects, while new and repurposed antibiotics have opened the door to more effective, shorter and less side effect-heavy treatments for drug susceptible TB and multidrug-resistant/extensively drug resistant TB as well as atypical mycobacterioses. This review investigates how these shorter and predominantly oral treatments, in the future, are expected to be used in combination with individualized precision medicine.

AB - Tuberculosis (TB) is still a major challenge for global health, but in recent years there have been several important developments in treatment options. Shorter treatment regimens for latent TB, based on conventional drugs, offer better adherence and fewer side effects, while new and repurposed antibiotics have opened the door to more effective, shorter and less side effect-heavy treatments for drug susceptible TB and multidrug-resistant/extensively drug resistant TB as well as atypical mycobacterioses. This review investigates how these shorter and predominantly oral treatments, in the future, are expected to be used in combination with individualized precision medicine.

M3 - Tidsskriftartikel

C2 - 35315752

VL - 184

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 10

M1 - V10210783

ER -

ID: 301455279